-
Mashup Score: 0
Deferred cytoreductive nephrectomy may still play a role in metastatic kidney cancer treatment despite use of immunotherapy.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0
“The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there’s a high concordance [between] MRD positivity and patients having progressive disease,” says Alan Tan, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD. @alantanmd @VUMCurology @VUMC_Cancer #kcsm https://t.co/cvmzAZ7B3X
-
-
Mashup Score: 1
“What we show in our research is that cancers develop in different ways, depending on what the underlying genetic change is,” says Taryn Treger.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
"What we show in our research is that cancers develop in different ways depending on what the underlying genetic change is," says Taryn Treger on the development of Wilms tumor. #kcsm https://t.co/Byp6E1sLHt
-
-
Mashup Score: 0
At a median follow-up of 24.3 months, the confirmed objective response rate was 70%.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The combination of belzutifan and cabozantinib elicited durable responses with manageable toxicities in treatment-naive patients with ccRCC, according to data from the phase 2 LITESPARK-003 trial. #kcsm @DrChoueiri https://t.co/KR9TmkGpOz
-
-
Mashup Score: 0
The combination of belzutifan and cabozantinib has demonstrated “promising” antitumor activity in treatment-naive patients with advanced clear-cell RCC, according to researchers.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
The combination of belzutifan and cabozantinib has demonstrated “promising” antitumor activity in treatment-naive patients with advanced clear-cell renal cell carcinoma. #kcsm https://t.co/2koPVEhzZt
-
-
Mashup Score: 0Top 10 kidney cancer stories in 2024 - 1 month(s) ago
As the year comes to a close, we revisit some of this year’s top content on the management of renal cancer.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Look back on the top 10 kidney cancer stories of 2024. #kcsm https://t.co/lkoYOsEk8a
-
-
Mashup Score: 0Cellular structures show link with survival outcomes in ccRCC - 1 month(s) ago
Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Findings from a recent study indicate that patterns of nuclear speckles may be correlated with clinical outcomes in ccRCC. #kcsm @CSHL @PennUrology https://t.co/dGwS8tgWX0
-
-
Mashup Score: 0First patient dosed in phase 1 trial of ADI-270 in ccRCC - 2 month(s) ago
Initial data from the trial are expected to be released in the first half of 2025.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The first patient has been dosed in a phase 1 trial of ADI-270 in patients with relapsed or refractory ccRCC. #kcsm https://t.co/LTWagDlUTy
-
-
Mashup Score: 0
At the 2024 LUGPA annual meeting, Gautam Jayram, MD, reviewed important developments therapeutics and diagnosis and staging.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
Therapeutic options to treat intermediate-risk and BCG-unresponsive bladder cancer, such as medications and ablative therapies, are expanding, and novel PET tracers enable improved diagnosis and staging of clear cell renal cell carcinoma. https://t.co/hNwXyS47NB #kcsm
-
-
Mashup Score: 0
At the 2024 LUGPA annual meeting, Gautam Jayram, MD, reviewed important developments therapeutics and diagnosis and staging.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
Therapeutic options to treat intermediate-risk and BCG-unresponsive bladder cancer, such as medications and ablative therapies, are expanding, and novel PET tracers enable improved diagnosis and staging of clear cell renal cell carcinoma. https://t.co/hNwXyS47NB #kcsm
-
Deferred cytoreductive nephrectomy may improve survival the most in patients with clear cell metastatic renal cell carcinoma (mRCC), according to a new study. #kcsm https://t.co/SWNMIQkJtl